Chatbot for Online Support Groups to Treat Tobacco Addiction
Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Apr 23, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how an intelligent chatbot can help people quit smoking by enhancing online support groups. Participants will be divided into two groups: one group will use a support group with the chatbot that can respond to questions and encourage discussion, while the other group will use a more basic automated message system that only posts daily discussion topics. The aim is to see if the chatbot can make the support group experience more helpful for those trying to quit tobacco.
To join the study, participants should be cigarette smokers aged 18 to 75 who are ready to quit within 10 days. They need to have a smartphone with unlimited data, be comfortable using text and social media, and have a minimum smoking history. Participants can expect to engage in discussions about quitting smoking and receive support from both the group and the chatbot. This trial is not yet recruiting, but it aims to find new ways to support people in their journey to quit tobacco.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cigarette smokers (can also use e-cigarettes)
- • Ages 18-75 years
- • English speaking
- • Smart phone with unlimited data
- • 100 cigarettes lifetime
- • Prepared to quit smoking within 10 days of study start
- • Active text and email
- • Use of social media or group messaging
- • Home address provided
- • Contact information for a collateral provided
- • Setup of a GroupMe account for study
- Exclusion Criteria:
- • No NRT health contraindications
- • 5+ cigarettes per day
- • Not an illicit drug user
- • Not a daily marijuana/cannabis user
About University Of California, Irvine
The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Cornelia A. Pechmann, PhD
Principal Investigator
University of California, Irvine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported